


PRODUCT INFORMATION



PRT060318

Item No. 22476

CAS Registry No.: 1194961-19-7
Formal Name: 2-[[[(1R,2S)-2-aminocyclohexyl]amino]-4-[[3-methylphenyl]amino]-5-pyrimidinecarboxamide
Synonyms: P142-76, PRT318
MF: C₁₈H₂₄N₆O
FW: 340.4
Purity: ≥98%
UV/Vis.: λ_{max}: 250, 288 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PRT060318 is supplied as a crystalline solid. PRT060318 is soluble in the organic solvent DMF, which should be purged with an inert gas. The solubility of PRT060318 in DMF is approximately 3 mg/ml.

PRT060318 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PRT060318 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PRT060318 has a solubility of approximately 0.03 mg/ml in a 1:30 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PRT060318 is a potent and selective inhibitor of spleen tyrosine kinase (Syk; IC₅₀ = 4 nM).^{1,2} It is selective, inhibiting 92% of Syk activity, while other kinases retain >70% activity, at a concentration of 50 nM in a panel of 270 kinases.² PRT060318 inhibits convulxin-induced aggregation of human platelet-rich plasma (IC₅₀ = 2.5 μM) *in vitro* and prevents thrombosis in a transgenic mouse model of heparin-induced thrombocytopenia. It induces chronic lymphocytic leukemia (CLL) B cell apoptosis and inhibits the secretion of chemokines CCL3, CCL4, and CXCL13.³ PRT060318 also inhibits CLL B cell chemotaxis and pseudoemperipolesis.

References

1. Woodford, M.R., Dunn, D.M., Blanden, A.R., *et al.* The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. *Nat. Commun.* **7**, 12037 (2016).
2. Archari, G.A. and Ramesh, R. Characterization of bacteria degrading 3-hydroxy palmitic acid methyl ester (3OH-PAME), a quorum sensing molecule of *Ralstonia solanacearum*. *Lett. Appl. Microbiol.* **60**(5), 447-455 (2015).
3. Hoellenriegel, J., Coffey, G.P., Sinha, U., *et al.* Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. *Leukemia* **26**(7), 1576-1583 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/18/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM